Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 40, Issue 4, Pages 549-564Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2020.07.003
Keywords
Severe asthma; Anti IL-33; Benralizumab; Dupilumab; Mepolizumab; Omalizumab; Reslizumab; Tezepelumab
Categories
Funding
- CRUI2020